About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PRQR - ProQR Therapeutics N...| Previous Close | $4.79 | Open | $4.84 |
| Volume | 53.9K | Market Cap | 241.69M |
| Yield | Last Dividend |
| Usher Syndrome Type 2 Treatment Market O... | 09/30/20 |
| The company profiles of all the key players and brands that are dominating the Usher Syndrome Type 2 Treatment Market have been taken into considerati... | |
| ProQR (PRQR) Reports Q1 Loss, Lags Reven... | 05/07/20 |
| ProQR (PRQR) delivered earnings and revenue surprises of 23.91% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clue... | |
| ProQR (PRQR) Begins Dosing in Phase I/II... | 12/12/19 |
| ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant... | |
| Will ProQR Therapeutics Continue to Surg... | 10/23/19 |
| As of late, it has definitely been a great time to be an investor ProQR Therapeutics. | |
| ProQR Therapeutics Enters Oversold Terri... | 10/01/19 |
| ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. | |
| The Daily Biotech Pulse: PhaseBio Leaps ... | 09/25/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 24)... | |
| ProQR Therapeutics: Near-Term Readout On... | 05/22/19 |
| No summary available. | |
| ProQR (PRQR) Reports Q1 Loss, Misses Rev... | 05/08/19 |
| ProQR (PRQR) delivered earnings and revenue surprises of -13.89% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clu... | |
| ProQR Announces Financial Results for th... | 05/08/19 |
| LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ: PRQR ), a company dedicated to changing live... | |
| ProQR Initiates Dosing in Phase II/III E... | 04/16/19 |
| ProQR Therapeutics (PRQR) initiates dosing in the phase II/III study on sepofarsen, its lead pipeline candidate for LCA 10, the most common genetic ca... | |
| ProQR to Present at the H.C. Wainwright ... | 04/01/19 |
| LEIDEN, Netherlands and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ: PRQR ), a company dedicated to changing ... | |
| ProQR spins out DEB unit | 03/26/19 |
| No summary available. | |
| RNA Therapeutics: The Triumphant Return ... | 03/07/19 |
| No summary available. | |
| ProQR reports Q4 results | 02/27/19 |
| No summary available. | |
| ProQR Therapeutics (PRQR) Investor Prese... | 01/30/19 |
| No summary available. | |
| CSX, ACB and TNXP among notable after ho... | 01/16/19 |
| No summary available. | |
| CSX, ACB and TNXP among notable after ho... | 01/16/19 |
| No summary available. | |
| Selloff continues in ProQR Therapeutics,... | 01/10/19 |
| No summary available. | |
| Selloff continues in ProQR Therapeutics,... | 01/10/19 |
| No summary available. | |
| MiMedx Group and Axsome Therapeutics amo... | 01/08/19 |
| No summary available. | |
| MiMedx Group and Axsome Therapeutics amo... | 01/08/19 |
| No summary available. | |
| ProQR +3% on receiving Fast Track design... | 01/02/19 |
| No summary available. | |
| ProQR +3% on receiving Fast Track design... | 01/02/19 |
| No summary available. | |
| ProQR Therapeutics added to NBI | 12/24/18 |
| No summary available. | |
| Buy rating | 08/11/20 |
| Chardan Capital maintains Buy rating and lowers Price Target from $25.00 to $20.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Value Investing | Flying Colors | 88.00 % | Subscribe |
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Basura | Monkey Business | 59.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
